title: Evaluating innovation. Part 2: Development in neurosurgery.
abstract: OBJECT Patients, practitioners, payers, and regulators are advocating for reform in how medical advances are evaluated. Because surgery does not adhere to a standardized developmental pathway, how the medical community accepts a procedure remains unclear. The authors developed a new model, using publication data and patterns, that quantifies this process. Using this technique, the authors identified common archetypes and influences on neurosurgical progress from idea inception to acceptance. METHODS Seven neurosurgical procedures developed in the past 15-25 years were used as developmental case studies (endovascular coil, deep brain stimulation, vagus nerve stimulation, 1,3-bis(2-chloroethyl)-l-nitrosourea wafer, and 3 radiosurgery procedures), and the literature on each topic was evaluated. A new metric the authors termed "progressive scholarly acceptance" (PSA) was used as an end point for community acceptance. PSA was reached when the number of investigations that refine or improve a procedure eclipsed the total number of reports assessing initial efficacy. Report characteristics, including the number of patients studied, study design, and number of authoring groups from the first report to the point of PSA, were assessed. RESULTS Publication data implicated factors that had an outsized influence on acceptance. First, procedural accessibility to investigators was found to influence the number of reports, number of patients studied, and number of authoring groups contributing. Barriers to accessibility included target disease rarity, regulatory restrictions, and cost. Second, the ease or difficulty in applying a randomized controlled trial had an impact on study design. Based on these 2 factors, 3 developmental archetypes were characterized to generally describe the development of surgery. CONCLUSIONS Common surgical development archetypes can be described based on factors that impact investigative methods, data accumulation, and ultimate acceptance by society. The approach and proposed terminologies in this report could inform future procedural development as well as any attempts to regulate surgical innovation.
authors.affiliation: Department of Neurosurgery, NYU Langone Medical Center, New York, New York.
authors.forename: Zane
authors.initials: Z
authors.lastname: Schnurman
authors.affiliation: Department of Neurosurgery, NYU Langone Medical Center, New York, New York.
authors.forename: Douglas
authors.initials: D
authors.lastname: Kondziolka
mesh_terms: D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000556:secondary / Q000601:surgery; D002330:Carmustine / Q000008:administration & dosage / Q000627:therapeutic use; D046690:Deep Brain Stimulation / Q000639:trends; D003863:Depression / Q000601:surgery; D004059:Diffusion of Innovation; D057510:Endovascular Procedures / Q000639:trends; D006801:Humans; D008579:Meningioma / Q000601:surgery; D009493:Neurosurgery / Q000191:economics / Q000639:trends*; D010342:Patient Acceptance of Health Care; D011643:Publishing / Q000639:trends; D016634:Radiosurgery / Q000639:trends; D016032:Randomized Controlled Trials as Topic; D012107:Research Design; D055536:Vagus Nerve Stimulation / Q000639:trends
chemical_list: D018906:Antineoplastic Agents, Alkylating; D002330:Carmustine
keywords: BCNU = 1,3-bis(2-chloroethyl)-l-nitrosourea; CMS = Centers for Medicare and Medicaid Services; DBS = deep brain stimulation; ET = essential tremor; GDC = Guglielmi detachable coil; LCD = local coverage determination; PSA = progressive scholarly acceptance; RCT = randomized controlled trial; SRS = stereotactic radiosurgery; TN = trigeminal neuralgia; VNS = vagus nerve stimulation; innovation; model; neurosurgery; science